1. Home
  2. BIAF vs ENSC Comparison

BIAF vs ENSC Comparison

Compare BIAF & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIAF
  • ENSC
  • Stock Information
  • Founded
  • BIAF 2014
  • ENSC 2003
  • Country
  • BIAF United States
  • ENSC United States
  • Employees
  • BIAF N/A
  • ENSC N/A
  • Industry
  • BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • ENSC Biotechnology: Pharmaceutical Preparations
  • Sector
  • BIAF Health Care
  • ENSC Health Care
  • Exchange
  • BIAF Nasdaq
  • ENSC Nasdaq
  • Market Cap
  • BIAF 7.6M
  • ENSC 6.4M
  • IPO Year
  • BIAF 2022
  • ENSC N/A
  • Fundamental
  • Price
  • BIAF $3.24
  • ENSC $2.46
  • Analyst Decision
  • BIAF Hold
  • ENSC
  • Analyst Count
  • BIAF 1
  • ENSC 0
  • Target Price
  • BIAF N/A
  • ENSC N/A
  • AVG Volume (30 Days)
  • BIAF 7.6M
  • ENSC 149.6K
  • Earning Date
  • BIAF 11-13-2025
  • ENSC 11-11-2025
  • Dividend Yield
  • BIAF N/A
  • ENSC N/A
  • EPS Growth
  • BIAF N/A
  • ENSC N/A
  • EPS
  • BIAF N/A
  • ENSC N/A
  • Revenue
  • BIAF $7,681,059.00
  • ENSC $7,413,722.00
  • Revenue This Year
  • BIAF N/A
  • ENSC N/A
  • Revenue Next Year
  • BIAF $20.04
  • ENSC $1,354.55
  • P/E Ratio
  • BIAF N/A
  • ENSC N/A
  • Revenue Growth
  • BIAF 4.99
  • ENSC 415.58
  • 52 Week Low
  • BIAF $2.34
  • ENSC $1.62
  • 52 Week High
  • BIAF $67.12
  • ENSC $14.67
  • Technical
  • Relative Strength Index (RSI)
  • BIAF 53.34
  • ENSC 66.12
  • Support Level
  • BIAF $2.36
  • ENSC $2.35
  • Resistance Level
  • BIAF $7.29
  • ENSC $2.64
  • Average True Range (ATR)
  • BIAF 0.63
  • ENSC 0.16
  • MACD
  • BIAF -0.30
  • ENSC 0.02
  • Stochastic Oscillator
  • BIAF 23.73
  • ENSC 76.79

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: